Grinlinton M, Furkert C, Maurice A, Angelo N, Booth M. Gastroesophageal signet ring cell carcinoma morbidity and mortality: A retrospective review. World J Gastrointest Surg 2024; 16(6): 1629-1636 [DOI: 10.4240/wjgs.v16.i6.1629]
Corresponding Author of This Article
Megan Grinlinton, FRACS (Gen Surg), MBChB, Doctor, Department of General Surgery, North Shore Hospital, 124 Shakespeare Road, Auckland 0620, New Zealand. megan.grinlinton@gmail.com
Research Domain of This Article
Surgery
Article-Type of This Article
Retrospective Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastrointest Surg. Jun 27, 2024; 16(6): 1629-1636 Published online Jun 27, 2024. doi: 10.4240/wjgs.v16.i6.1629
Gastroesophageal signet ring cell carcinoma morbidity and mortality: A retrospective review
Megan Grinlinton, Chris Furkert, Andrew Maurice, Neville Angelo, Michael Booth
Megan Grinlinton, Chris Furkert, Andrew Maurice, Michael Booth, Department of General Surgery, North Shore Hospital, Auckland 0620, New Zealand
Neville Angelo, Department of Pathology, North Shore Hospital, Auckland 0620, New Zealand
Author contributions: Grinlinton M, Furkert C and Booth M conceptualised and designed the research; Grinlinton M and Angelo N acquired the demographic and clinical data; Furkert C and Grinlinton M collected the clinical data; Maurice A performed data analysis; Grinlinton M wrote the paper; Grinlinton M and Maurice A have played important roles in the data interpretation and manuscript preparation as the authors; Maurice A was instrumental and responsible for data analysis and interpretation; Grinlinton M was responsible for literature search, preparation and submission of the current version of the manuscript. All authors have read and approve the final manuscript.
Institutional review board statement: This study was reviewed and approved by the New Zealand Health and Disability Ethics Committee (No. 15291).
Informed consent statement: Informed consent was not required due to the retrospective and anonymous nature of this study.
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Megan Grinlinton, FRACS (Gen Surg), MBChB, Doctor, Department of General Surgery, North Shore Hospital, 124 Shakespeare Road, Auckland 0620, New Zealand. megan.grinlinton@gmail.com
Received: January 19, 2024 Revised: April 23, 2024 Accepted: April 28, 2024 Published online: June 27, 2024 Processing time: 162 Days and 6.5 Hours
Abstract
BACKGROUND
Upper gastrointestinal (GI) signet ring cell carcinomas (SRCC) confer a poor prognosis. The benefit of operative intervention for this patient group is controversial in terms of overall survival.
AIM
To investigate factors relating to survival in patients with upper GI SRCC.
METHODS
A retrospective, tertiary, single-centre review of patients who were diagnosed with oesophageal, gastroesophageal junction and gastric SRCC was performed. The primary outcome was to compare mortality of patients who underwent operative management with those who had nonoperative management. Secondary outcomes included assessing the relationship between demographic and histopathological factors, and survival.
RESULTS
One hundred and thirty-one patients were included. The one-year survival for the operative group was 81% and for the nonoperative group was 19.1%. The five-year survival in the operative group was 28.6% vs 1.5% in the nonoperative group. The difference in overall survival between groups was statistically significant (HR 0.19, 95%CI (0.13-0.30), P < 0.001). There was no difference in survival when adjusting for age, smoking status or gender. On multivariate analysis, patients who underwent surgical management, those with a lower stage of disease, and those with a lower Charlson Comorbidity Index (CCI) had significantly improved survival.
CONCLUSION
Well-selected patients with upper GI SRCC appear to have reasonable medium-term survival following surgery. Offering surgery to a carefully selected patient group may improve the outcome for this disease.
Core Tip: This retrospective review confirms that in a select group of patients, surgical management for upper gastrointestinal signet ring cell carcinoma may provide a survival benefit and should be considered. Demographic factors such as age, smoking status and gender do not have a relationship with survival. Patients who had surgical management, those with a lower Charlson Comorbidity Index, and those with a lower stage of disease had significantly improved survival.
